Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
Randomized clinical trial of low dose suramin intravenous infusions for treatment of autism spectrum disorder.
Journal: Annals of general psychiatry
Published: March 10, 2023
Comparison of Long-Term Efficacy and Safety of Esketamine Nasal Spray Plus Oral Antidepressant in Younger Versus Older Patients With Treatment-Resistant Depression: Post-Hoc Analysis of SUSTAIN-2, a Long-Term Open-Label Phase 3 Safety and Efficacy Study.
Journal: The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
Published: April 08, 2021
Benefit-Risk Assessment of Esketamine Nasal Spray vs. Placebo in Treatment-Resistant Depression.
Journal: Clinical pharmacology and therapeutics
Published: April 21, 2020
Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II).
Journal: The international journal of neuropsychopharmacology
Published: April 07, 2020
Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study.
Journal: Focus (American Psychiatric Publishing)
Published: February 05, 2020
Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Journal: The Journal of clinical psychiatry
Published: December 02, 2019
Approval of esketamine for treatment-resistant depression.
Journal: The lancet. Psychiatry
Published: November 28, 2019
Comment on a Word to the Wise About Intranasal Esketamine.
Journal: The American journal of psychiatry
Published: October 02, 2019
Cognitive functioning in adolescents with schizophrenia treated with paliperidone extended-release: 6-Month exploratory analysis from an open-label, single-arm safety study.
Journal: Schizophrenia research. Cognition
Published: July 28, 2019
Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
Journal: JAMA psychiatry
Published: June 06, 2019
Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
Journal: The American journal of psychiatry
Published: May 22, 2019
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2).
Journal: The Journal of clinical psychiatry
Published: April 26, 2019
Last Updated: 09/26/2026